Technology and Innovation Platforms, key elements of Spain’s R&D&I system

The Spanish Technological Platform for Innovative Medicines, led by Farmaindustria, has been promoting public-private collaboration projects in clinical and pre-clinical research since 2005. “Spain currently occupies a position of international leadership in clinical research that needs to be reinforced in the face of growing competition from regions such as the USA and Asia-Pacific”, emphasised Farmaindustria’s […]

HPV: THE SUCCESS OF A VACCINE TO PREVENT CANCER AND WHY IT IS IMPORTANT TO SPREAD IT WORLDWIDE

Human papillomavirus is responsible for 95% of cervical tumours. Since 2006, several vaccines have been licensed that can prevent most cases. In Spain, the autonomous communities first introduced the vaccine for girls, and from the end of 2023, boys will also be vaccinated throughout the country. More than 30,000 European women are diagnosed with cervical […]

The health sector, essential for the well-being of the population and an economic engine for society

fundacionidis.com The ecosystem of the private healthcare sector transcends the field of healthcare and has an impact on society and on the productive sectors of the country’s economy: in 2021, healthcare expenditure reached 10.4% of GDP, with at least 3.1% of this being of private origin. 7.5% of employees in Spain work in activities related […]

Spain takes, on average, two years to approve a drug for a minority disease

There are 146 orphan drugs approved by the European Medicines Agency. Spain has only 81 in its catalogue. It has rejected funding for 25 and is studying 17 others. ondacero.es There are two main anxieties for those suffering from a so-called rare or minority disease and their families. One is to name the disease, and […]

22% of clinical trials underway in Spain seek new treatments for rare diseases

Research into new drugs for rare diseases has multiplied in recent years. In Spain, industry drives 90% of clinical trials for this type of disease. One out of every three drugs with a new active ingredient authorised in Europe in 2023 was an orphan drug On World Rare Disease Day, celebrated on 29 February, we […]

The Andalusian Regional Government and Farmaindustria will promote R&D&I in health with a special focus on the promotion of clinical trials.

In a press release, the Andalusian Regional Government highlights the joint commitment of both entities to continue advancing in the promotion of R&D&I, following the meeting of the Secretary General for Public Health and Health Research, Development and Innovation of the Regional Ministry of Health and Consumer Affairs, Isaac Túnez, with the Governing Council of […]

Spain is the country with the highest participation in clinical trials of new drugs in Europe

Of the 1,944 clinical trials authorised in the European Union through the new European Information System, Spanish centres participated in 845, or 43% of the total. In addition, the Spanish Medicines Agency was responsible for coordinating the authorisation of 350 multinational trials, making Spain the leader in this field, ahead of Germany with 314 and […]

Europe calls latest cancer drugs “significant progress” for health

The European Medicines Agency has thus identified nine oncology approvals for 2023. The arrival of new treatments is directly linked to the pharmaceutical industry’s commitment to the fight against cancer. Survival in some tumour types now exceeds 90%. A new study by the Swedish Institute of Health Economics finds inequalities in access to screening, biomarkers […]

The Innovative Medicines Platform sets its roadmap for 2024 with the aim of turning Spain into a major biomedical innovation hub

The Technological Platform for Innovative Medicines – whose Coordination Committee is made up of 10 representatives from the pharmaceutical industry and 10 representatives from public research – defines its action plan for 2024 and debates advances and new developments in preclinical and clinical research and the use of data, among others. The Annual Conference of […]

A common catalogue of biomarkers in the National Health System is a great step forward for patients because it improves access to personalised medicine.

Farmaindustria welcomes the presentation by the Ministry of Health of the harmonised catalogue of genetic tests for the whole country. For this catalogue to become a useful tool for patients, it requires a standard that regulates its use and updating adapted to the approval of new therapies and the guarantee that it is implemented fairly […]